ProNephro AKI (NGAL)
Risk assessment of moderate to severe Acute Kidney Injury (pediatrics, 3 months-22 years)
CommercialFDA-Cleared
Key Facts
Indication
Risk assessment of moderate to severe Acute Kidney Injury (pediatrics, 3 months-22 years)
Phase
Commercial
Status
FDA-Cleared
Company
About BioPorto Diagnostics
BioPorto Diagnostics is a Copenhagen-based company focused on improving kidney health by addressing the critical unmet need for early detection of Acute Kidney Injury (AKI). Its core achievement is the development and commercialization of NGAL-based diagnostic tests, including the FDA-cleared ProNephro AKI for pediatric risk assessment and The NGAL Test™ for broader use. The company's strategy centers on expanding the clinical utility and geographic adoption of its NGAL platform through direct commercialization and strategic partnerships, such as its distribution agreement with Roche Diagnostics.
View full company profile